Phase II proof-of-concept trial of ALS 2200 [VLX 135] in combination with GSK 2336805 in treatment-naive patients with chronic, genotype 1 hepatitis C.

Trial Profile

Phase II proof-of-concept trial of ALS 2200 [VLX 135] in combination with GSK 2336805 in treatment-naive patients with chronic, genotype 1 hepatitis C.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2013

At a glance

  • Drugs JNJ 56914845 (Primary) ; VX 135 (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jul 2013 Status changed from planning to discontinued, as reported by a Vertex media release.
    • 06 Jan 2013 Planned initiation date changed from 1 Mar 2013 to 1 Jun 2013, according to a Vertex Pharmaceuticals media release.
    • 06 Jan 2013 Data is expected in the second half of 2013, according to a Vertex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top